SUBSCRIBE
SUBSCRIBE
News   Drug Development

Biogen Idec, Inc. (Massachusetts) Initiates Phase III Clinical Program Of Oral Compound BG-12 For Multiple Sclerosis

January 9, 2007 | 
1 min read
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen Idec (NASDAQ: BIIB) announced today that it has initiated the Phase III clinical program of BG-12, an oral fumarate in development for relapsing-remitting multiple sclerosis (MS).
Clinical research Phase 3
Biogen
MORE ON THIS TOPIC
pour-watered from the watering can banknotes dollars on a white background. Concept, investment, start-up business, startup, income growth.
Manufacturing
Roche pours $750M into Oregon manufacturing plant as obesity push expands
August 20, 2026
 · 
1 min read
 · 
Gabrielle Masson
Business competitive advantage of paper plane in new competitive, competitor individual pointing in different ways for new competitive advantage on 3D render. Advantage for new idea competition.
IPO
Scribe’s early-stage IPO standout defies biotech’s derisking trend
August 20, 2026
 · 
3 min read
 · 
Gabrielle Masson
Pictured: Rare disease ribbon with cut-outs of people
Rare diseases
Regeneron wins FDA approval to challenge Ipsen for rare bone disease market
August 20, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Checklist, Icon, Clipboard, List, Questionnaire
Gene therapy
Ultragenyx bags first gene therapy approval as previously rejected Sanfilippo asset awaits decision
August 20, 2026
 · 
2 min read
 · 
Nick Paul Taylor